Kirkwood JM - Search Results

1

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.

Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, Kirkwood JM. Hauschild A, et al. Among authors: kirkwood jm. Cancer. 2008 Mar 1;112(5):982-94. doi: 10.1002/cncr.23251. Cancer. 2008. PMID: 18236459 Free article. Review.

2

Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.

Ernstoff MS, Gooding W, Nair S, Bahnson RR, Miketic LM, Banner B, Day R, Whiteside T, Titus-Ernstoff L, Kirkwood JM. Ernstoff MS, et al. Among authors: kirkwood jm. Cancer Res. 1992 Feb 15;52(4):851-6. Cancer Res. 1992. PMID: 1737346 Clinical Trial.

3

Interferon adjuvant therapy of melanoma.

Kirkwood JM, Wazer D, Rosenstein M. Kirkwood JM, et al. Cancer. 1997 May 1;79(9):1843-6. doi: 10.1002/(sici)1097-0142(19970501)79:9<1843::aid-cncr33>3.0.co;2-w. Cancer. 1997. PMID: 9129006 No abstract available.

4

Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies.

Kirkwood JM. Kirkwood JM. Eur J Cancer. 1998 Jul;34 Suppl 3:S12-7. doi: 10.1016/s0959-8049(97)10159-9. Eur J Cancer. 1998. PMID: 9849403 Review.

5

Adjuvant interferon in the treatment of melanoma.

Kirkwood JM. Kirkwood JM. Br J Cancer. 2000 May;82(10):1755-6. doi: 10.1054/bjoc.1999.1225. Br J Cancer. 2000. PMID: 10817514 Free PMC article. Clinical Trial. No abstract available.

6

An update on adjuvant interferon for melanoma.

Gray RJ, Pockaj BA, Kirkwood JM. Gray RJ, et al. Among authors: kirkwood jm. Cancer Control. 2002 Jan-Feb;9(1):16-21. doi: 10.1177/107327480200900103. Cancer Control. 2002. PMID: 11907462 Free article. Review.

7

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.

Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L. Kirkwood JM, et al. J Clin Oncol. 2002 Sep 1;20(17):3703-18. doi: 10.1200/JCO.2002.03.052. J Clin Oncol. 2002. PMID: 12202672 Review.

8

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R. Kirkwood JM, et al. Cancer. 2002 Sep 1;95(5):1101-12. doi: 10.1002/cncr.10775. Cancer. 2002. PMID: 12209697 Free article. Clinical Trial.

9

Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.

Agarwala SS, Kirkwood JM. Agarwala SS, et al. Among authors: kirkwood jm. Cancer. 2003 Jan 1;97(1):121-7. doi: 10.1002/cncr.11041. Cancer. 2003. PMID: 12491513 Free article. Clinical Trial.

10

Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.

Radin AI, Kim HT, Grant BW, Bennett JM, Kirkwood JM, Stewart JA, Hahn RG, Dutcher JP, Wiernik PH, Oken MM; Eastern Cooperative Oncology Group. Radin AI, et al. Among authors: kirkwood jm. Cancer. 2003 Jul 1;98(1):100-9. doi: 10.1002/cncr.11486. Cancer. 2003. PMID: 12833462 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

600 results

Search Page